Bookmark and Share

Last Minute:          For more news, click here.

Remember me? 

Show More News:
 Watch more news

News search related to the stock ADC Telecommunica (ordered by date):

ADC Therapeutics (NYSE:ADCT) Upgraded to Hold by Zacks Investment Research  MarketBeat ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTAŽ (loncastuximab tesirine-lpyl) in Japan  Business Wire ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript  Motley Fool 52 Biggest Movers From Friday | Markets Insider  Markets Insider Latest business liquidations in Unincorporated ACT  Daily Telegraph ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors  Business Wire ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million  Business Wire ADC Therapeutics Becomes Oversold (ADCT)  Nasdaq ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTAŽ  Business Wire ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates  Business Wire Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTAŽ in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma  Business Wire Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China  PRNewswire ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma  Business Wire Viettel still Vi?t Nam's fastest mobile provider in Q4  EIN News ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTAŽ  Business Wire TuSimple Develops Autonomous Domain Controller Using NVIDIA DRIVE Orin to Bring Level 4 Autonomous Trucking to Market at Scale  PRNewswire ADC Therapeutics Announces FDA Approval of ZYNLONTA? (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma  BioSpace ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore  Business Wire ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma  Business Wire ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield  Business Wire Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer  Business Wire ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates  Business Wire Coming together for Zynlonta  Cancer Research UK Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors  Yahoo Finance ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Recommendation of "Buy" from Analysts  MarketBeat ADC Therapeutics to develop anti-cancer drugs in new White City Campus centre  Imperial College London ADC Therapeutics Receives FDA Approval For Zynlonta  Contract Pharma Internet infrastructure to get strong investment this year ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors  Business Wire Bergenbio dream lives on, despite Genmab's broken Axl  Vantage ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.  Business Wire ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma  Business Wire Fitch Affirms Liquid Telecom at 'B+'; Outlook Stable  Fitch Ratings ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma  Business Wire Synaffix and Mersana add license options for six ADC targets to existing deal  The Pharma Letter A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO  Endpoints News ADC Therapeutics Announces Proposed Public Offering  Business Wire ADC Therapeutics Announces Pricing of Upsized Initial Public Offering  GlobeNewswire Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma  OncLive ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma  GlobeNewswire Africa Data Centres Opens 10MW Colocation Facility in Lagos  Data Center Knowledge The proposed Manipur (hill areas) ADC bill, 2021 vis-ŕ-vis The Original Act  Nagaland Post Liquid's ADC to build 'biggest African data centre' outside South Africa  Capacity Media ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting  Business Wire Manipur: Tribal student bodies announce series of protests in hill districts over ADC Bill  The Indian Express AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data  FierceBiotech Loncastuximab Tesirine Produces Durable Response in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma  Hematology Advisor Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders  PRNewswire Synaffix to Present Key ADC Technology Data on SYNtecan ETM Linker-Payload at World ADC Conference  PRNewswire ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress  Business Wire ADC to pump billions into 10 new Africa data centres  TechCentral ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield  GlobeNewswire ADC Therapeutics and Freenome Enter Biomarker Development  GlobeNewswire ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors  GlobeNewswire ADC Therapeutics Cuts Price In Second IPO Attempt  Seeking Alpha Genmab and ADC Therapeutics Announce Amended Agreement for  GlobeNewswire TI's new precision wideband ADC pushes data-acquisition performance higher while cutting size and power consumption in half  PRNewswire ADC Therapeutics Begins U.S. IPO Process  Seeking Alpha 2023 Presidential Candidates: Hidden Hands Now Publicly Raised  Investors King Ltd ADC's $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon  Xconomy Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer  PRNewswire ADC Therapeutics prices IPO at $19 a share, above the price range  MarketWatch ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma  Business Wire IPO, check: Now, ADC Therapeutics files for lonca approval  FierceBiotech ADC Therapeutics taps Freenome to chart biomarkers for its lead lymphoma drug  FierceBiotech ADC Therapeutics to Participate in the Jefferies London Healthcare Conference  Business Wire Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC  PRNewswire New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies  Canada NewsWire ADC Therapeutics raise $76m in Series E expansion  European Biotechnology ADC Therapeutics cleared to resume US trial of camidanlumab tesirine  The Pharma Letter The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference  Benzinga ADC Therapeutics and Adagene Announce License Agreement  GlobeNewswire ADC Consortium to boost APAC IoT connections with new submarine cable  FutureIoT Innovent Announces License Agreement with Synaffix in an ADC Technology Deal  PRNewswire Synaffix collaboration with ADC Therapeutics expanded  The Pharma Letter ProfoundBio Announces Completion of More Than $55 million Series A Financing to Advance Novel Antibody-Drug Conjugate (ADC) Portfolio  PRNewswire Innovate with C#; Microsoft ADC Set to Host Programmers and Developers in Africa  PRNewswire Seeking Alpha Catalyst Watch  Seeking Alpha Antibody-Drug Conjugates (ADCs) Market Size to Reach USD 20.01 Billion in 2028 | Increasing Prevalence of Cancer Along with Growing Geriatric Population are Significant Factor Driving Industry Demand, says Emergen Research  PRNewswire ADC Therapeutics (NYSE:ADCT) shareholders are up 10% this past week, but still in the red over the last year  Simply Wall St ADC Therapeutics set to go public  European Biotechnology Auto Scale your Applications with Citrix ADC on Google Cloud  ITPro Today Npower: FG Yet to Engage Exited Npower Beneficiaries  Investors King Ltd ADC Therapeutics raises US$200m in private financing  European Biotechnology ADC Therapeutics Announces Final Close of Series E Financing Expansion  BioSpace Tyco Electronics to buy ADC Telecom for $1.25 billion  MarketWatch ATSUM takes ADC Bill demand to tribal villages : 18th oct21 DDB Worldwide Named 2021 Network of the Year by ADC  PRNewswire Identifying DLBCL Patients Most Likely to Benefit from ADCT-402 Goal of Partnership  Lymphoma News Today Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 - Benzinga  Benzinga Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers  PRNewswire ADC Therapeutics SA (ADCT) Stock Price Today, Quote & News  Seeking Alpha 5 Dividend Stocks To Act As A Ballast For Your Portfolio  Seeking Alpha FDA Approves Loncastuximab Tesirine for Relapsed/Refractory Large B-Cell Lymphoma  OncLive TI bridges the high-speed and precision gap with new SAR ADC family, including the industry's fastest 18-bit ADC ADC Therapeutics axes HER2 program  BioPharma Dive FDA Removes Partial Clinical Hold on Camidanlumab Tesirine Phase 2 Trial  Targeted Oncology EQS-News: ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia  Markets Insider Antibody-Drug Conjugates: Cancer Therapies to Watch  Cancer Therapy Advisor

Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2022 -, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources